Nalagenetics
David Rusli's work experience begins with their current role as a Solutions Engineer at Nalagenetics, starting in May 2022. Prior to this, they worked at PT. Control Systems Arena Para Nusa from November 2019 to November 2021 as a Technical Service Engineer, where they provided preventive maintenance for existing DCS systems and troubleshooted and repaired various problems.
In 2018, David worked as a Research and Development Engineer at Prime Technology Indonesia for a brief period, where they were involved in conceptual design, fabrication, and performance validation of a 2-DOF motion platform.
Before that, they interned at Alensys Engineering GmbH from March 2017 to August 2017, where they gained experience in interpreting blueprints, creating CAD models, and calculating energy savings for Biogas plant projects.
Lastly, they interned at PT. Roland Golden Age in January 2016 to February 2016, where they collaborated with the leadership team, conducted research, and gathered information for fume hood system implementation.
David Rusli completed their Bachelor's degree in Mechatronics, Robotics, and Automation Engineering from Swiss German University, which they attended from 2014 to 2019. In 2017, they briefly studied at Fachhochschule Südwestfalen, although no degree or field of study information is provided for this period. Prior to their university studies, David attended Canisius College (Kolese Kanisius) from 2011 to 2014, where they focused on science. It is unclear whether they obtained a degree during this time.
In addition to their formal education, David Rusli has also obtained a Jira Service Management Fundamentals Badge from Atlassian in November 2022.
This person is not in any offices
Nalagenetics
Nalagenetics was built with the passion to give access to personalized prescription to as many people as possible. Two of the co-founders have seen and felt firsthand the betrayal of drugs that were supposed to cure their family members, but instead caused them permanent side effects. It was then that they realized, without understanding how to best use them, innovations in pharma and biotech, meant little to the people who need it most.